Rheonix, Inc. to Give Keynote Lecture on Molecular Diagnostics

BUFFALO, N.Y.— The University at Buffalo’s New York State Center of Excellence in Bioinformatics & Life Sciences (CBLS) will host Rheonix, Inc., a molecular diagnostic company based in Ithaca, N.Y., to deliver September’s Life Sciences Commercialization Lecture.

The lecture will take place on Sept. 18 from 4 to 5 p.m. in the Bruce A. Holm Commons area (2nd floor), at the CBLS, 701 Ellicott Street, Buffalo.

Senior Vice President for Scientific and Clinical Affairs at Rheonix, Richard A. Montagna, PhD, FACB, will discuss the challenges associated with personalized medicine – a practice that uses a patient’s genetic makeup to identify the most effective prescriptions available for treatment. Montagna will focus on the technical, regulatory and reimbursement aspects of this specialized treatment.

Norma Nowak, PhD, director of science and technology at the CBLS, will facilitate the lecture and give an update on the Buffalo Institute for Genomics (BIG), a research initiative that brings UB together with the NY Genome Center in New York City as co-leaders in advancing genomics research and analysis.

The program will conclude with Michael Buck, PhD, associate professor at UB and director of the Stem Cell Sequencing Epigenomics Analysis Facility at the Western New York Stem Cell Culture and Analysis Center.

To register for this free event, visit personalized-medicine.eventbrite.com.

The CBLS is UB’s hub for life sciences innovation and technology-based economic development. Leveraging our resources, we drive scientific discovery, facilitate collaboration among academia, industry and the public sector. We help companies get the funding they need to thrive, scientists gain access to world-class facilities and create employment and investment opportunities that improve human health. Learn more at www.buffalo.edu/cbls